Acquired Megaesophagus

Acquired megaesophagus is a disorder of the esophagus characterized by diffuse dilation and decreased or absent peristalsis, leading to functional obstruction and regurgitation. It is distinguished from congenital megaesophagus, which presents in young animals, by its onset later in life. The condition can be idiopathic or secondary to various underlying diseases, including myasthenia gravis, hypoadrenocorticism, esophagitis, and neuromuscular disorders. The esophagus, a muscular tube connecting the pharynx to the stomach, relies on coordinated peristaltic contractions and relaxation of the lower esophageal sphincter (LES) to propel food and water. In megaesophagus, this coordinated motility is lost, resulting in esophageal dilation and accumulation of ingesta, which is then regurgitated. The condition can lead to severe complications such as aspiration pneumonia, malnutrition, and dehydration. Classification is based on etiology: congenital (present at birth or in young animals) versus acquired (developing later in life), and within acquired, further subdivided into idiopathic (no identifiable cause) and secondary (due to an underlying disease). The clinical significance is high, as it significantly impacts quality of life and can be life-threatening if complications arise.

The etiology of acquired megaesophagus is diverse and can be categorized into idiopathic and secondary causes. Idiopathic megaesophagus accounts for approximately 25-30% of cases in dogs and is a diagnosis of exclusion. Secondary causes include: 1) Neuromuscular disorders: Myasthenia gravis (MG) is the most common identifiable cause, accounting for up to 25% of acquired cases. It is an autoimmune disease where antibodies target acetylcholine receptors at the neuromuscular junction, leading to muscle weakness, including esophageal muscles. Other neuromuscular diseases include polymyositis, dermatomyositis, polyneuropathy, and muscular dystrophy. 2) Endocrine disorders: Hypoadrenocorticism (Addison's disease) is a well-recognized cause, likely due to electrolyte imbalances (hyponatremia, hyperkalemia) and glucocorticoid deficiency affecting muscle function. Hypothyroidism has been implicated but is controversial. 3) Esophagitis: Severe inflammation of the esophagus, often due to gastroesophageal reflux, ingestion of caustic substances, or chronic vomiting, can lead to fibrosis and motility dysfunction. 4) Toxins: Lead poisoning, botulism, and organophosphate toxicity can cause neuromuscular dysfunction. 5) Infectious diseases: Canine distemper virus, tetanus, and tick paralysis (toxin from Dermacentor species) can affect the nervous system and lead to megaesophagus. 6) Neoplasia: Tumors of the esophagus or mediastinum (e.g., thymoma, lymphoma) can cause physical obstruction or invade nerves. 7) Trauma: Injury to the vagus nerve or cervical spinal cord can disrupt esophageal innervation. 8) Drugs: Certain medications, such as corticosteroids (in rare cases) or anticholinergics, may impair esophageal motility. In cats, acquired megaesophagus is less common but can be associated with similar causes, including MG, dysautonomia, and esophagitis. The exact molecular triggers for idiopathic cases remain unknown, but genetic predisposition and immune-mediated mechanisms are suspected.

Acquired megaesophagus is predominantly a disease of dogs, with a higher incidence in certain breeds. In dogs, the condition is more common in large and giant breeds, such as Great Danes, German Shepherds, Golden Retrievers, Labrador Retrievers, and Irish Setters. However, it can occur in any breed. The age of onset is typically middle-aged to older dogs (mean age 7-9 years), but it can occur at any age. There is no strong sex predilection, though some studies suggest a slight male predominance. In cats, acquired megaesophagus is rare, with no specific breed predilection, and it tends to occur in older cats. The incidence of acquired megaesophagus is not well-documented, but it is considered an uncommon condition. The prevalence of underlying causes varies: myasthenia gravis is the most common identifiable cause in dogs, accounting for 20-30% of cases, while hypoadrenocorticism is found in 5-10%. Idiopathic cases constitute about 25-30%. Geographic variation may exist due to regional prevalence of infectious diseases (e.g., tick paralysis in endemic areas). There is no known seasonal pattern, except for tick-borne diseases. In terms of breed-specific genetic risk, certain breeds like the Great Dane have a higher risk of developing myasthenia gravis, which may predispose them to megaesophagus. The condition is not contagious, and there is no zoonotic potential.

The pathophysiology of acquired megaesophagus involves disruption of the normal esophageal motility, which is controlled by the somatic motor neurons of the vagus nerve and the myenteric plexus. The esophagus is composed of striated muscle in the cranial two-thirds in dogs and cats, and smooth muscle in the caudal third. Peristalsis is initiated by swallowing, which triggers a reflex arc involving the swallowing center in the medulla, vagal efferents, and the esophageal muscles. In megaesophagus, there is a failure of peristaltic contractions, leading to dilation and accumulation of ingesta. The underlying mechanisms depend on the etiology. In myasthenia gravis, autoantibodies bind to acetylcholine receptors at the neuromuscular junction, reducing the number of functional receptors and impairing muscle contraction. This results in weakness and fatigue of the esophageal muscles, leading to dilation. In hypoadrenocorticism, the deficiency of mineralocorticoids (aldosterone) leads to hyponatremia, hyperkalemia, and acidosis, which can impair neuromuscular function. Glucocorticoid deficiency may also contribute to muscle weakness. Esophagitis causes inflammation and fibrosis of the esophageal wall, which can disrupt the myenteric plexus and reduce compliance. Toxins like lead and botulinum toxin interfere with neurotransmitter release or receptor function. In idiopathic cases, the exact mechanism is unknown, but it is hypothesized to involve immune-mediated damage to the esophageal nerves or muscles. The dilation of the esophagus leads to stasis of food and saliva, which can cause regurgitation, aspiration pneumonia, and esophagitis. Chronic distension can further damage the esophageal wall, creating a vicious cycle. The lower esophageal sphincter may be normal or dysfunctional, but in many cases, it remains closed, contributing to the accumulation of contents.

Predisposing factors for acquired megaesophagus include: 1) Breed: Large and giant breeds are overrepresented, likely due to genetic predisposition to immune-mediated diseases like myasthenia gravis. 2) Age: Middle-aged to older dogs are more commonly affected, possibly due to increased risk of neoplasia and endocrine disorders. 3) Concurrent diseases: Animals with autoimmune diseases (e.g., systemic lupus erythematosus, polymyositis) are at higher risk. 4) Endocrine disorders: Hypoadrenocorticism and hypothyroidism (though controversial) can predispose to megaesophagus. 5) Environmental factors: Exposure to toxins (lead, organophosphates) or infectious agents (tick paralysis, distemper) increases risk. 6) Medications: Use of drugs that impair neuromuscular function (e.g., aminoglycosides, anticholinergics) may precipitate megaesophagus in susceptible individuals. 7) Dietary factors: Feeding habits, such as rapid eating or eating from elevated bowls, may exacerbate regurgitation but are not primary causes. 8) Stress: Stressful events may trigger clinical signs in animals with subclinical esophageal dysfunction. 9) Genetic factors: Certain breeds have a higher incidence of myasthenia gravis, which is a major cause. 10) Immunosuppression: Animals on immunosuppressive therapy may be more susceptible to infections that can cause megaesophagus. It is important to note that in many cases, no predisposing factor is identified, and the condition is deemed idiopathic.

The clinical signs of acquired megaesophagus are primarily related to regurgitation and its complications. Regurgitation is the hallmark sign, characterized by passive expulsion of undigested food or fluid from the esophagus, often shortly after eating. Unlike vomiting, regurgitation is not preceded by nausea, retching, or abdominal contractions. Owners may report that the animal appears to 'spit up' food or water. Other signs include: 1) Weight loss and poor body condition due to inadequate nutrient absorption. 2) Coughing, which may be due to aspiration pneumonia or tracheal compression from a dilated esophagus. 3) Nasal discharge, especially after eating, due to regurgitation of fluid into the nasopharynx. 4) Excessive salivation (ptyalism) and halitosis. 5) Dysphagia (difficulty swallowing) may be present, though some animals can swallow initially. 6) In severe cases, respiratory distress due to aspiration pneumonia, with fever, lethargy, and anorexia. 7) In cases secondary to myasthenia gravis, generalized muscle weakness, exercise intolerance, and megaphagia may be observed. 8) In hypoadrenocorticism, signs such as lethargy, weakness, vomiting, diarrhea, and collapse may be present. The onset can be acute or insidious. Physical examination may reveal a palpable dilation of the cervical esophagus (in some cases), crackles or wheezes on thoracic auscultation if pneumonia is present, and signs of dehydration or malnutrition. In chronic cases, there may be muscle wasting and poor coat condition. The severity of clinical signs correlates with the degree of esophageal dilation and the presence of complications.

Differential diagnoses for acquired megaesophagus include: 1) Congenital megaesophagus: Present in young animals, often due to developmental abnormalities of the esophagus. 2) Esophageal stricture: Caused by scarring from esophagitis, foreign bodies, or surgery; presents with regurgitation but imaging shows focal narrowing rather than diffuse dilation. 3) Esophageal foreign body: Acute onset of regurgitation, often with pain, and radiographs may show a radiopaque object. 4) Esophageal neoplasia: Tumors such as squamous cell carcinoma or leiomyoma can cause obstruction and dilation proximal to the mass; imaging and biopsy are diagnostic. 5) Vascular ring anomaly: Congenital condition in young animals, causing esophageal dilation cranial to the heart base; typically seen in puppies. 6) Hiatal hernia: Protrusion of the stomach into the thoracic cavity, leading to regurgitation and esophagitis; diagnosed by radiography or endoscopy. 7) Gastroesophageal reflux disease (GERD): Can cause esophagitis and secondary motility dysfunction, but primary megaesophagus is not present. 8) Myasthenia gravis: Can cause megaesophagus, but also presents with generalized weakness; diagnosis via acetylcholine receptor antibody titers. 9) Hypoadrenocorticism: Can cause megaesophagus, but also presents with electrolyte abnormalities and characteristic clinical signs. 10) Dysautonomia (Key-Gaskell syndrome): A disorder of the autonomic nervous system, more common in cats, causing esophageal dilation, urinary retention, and other autonomic signs. 11) Polymyositis: Inflammation of muscles, including esophageal muscles, leading to weakness and megaesophagus; diagnosed by muscle biopsy and elevated muscle enzymes. 12) Botulism: Toxin-induced neuromuscular paralysis, with acute onset of flaccid paralysis and megaesophagus. 13) Tick paralysis: Toxin from ticks causes ascending paralysis and megaesophagus; history of tick exposure and removal of tick leads to recovery. 14) Lead poisoning: Can cause neuropathy and megaesophagus; diagnosed by blood lead levels. 15) Esophagitis: Severe inflammation can lead to motility dysfunction, but usually there is a history of caustic ingestion or reflux. Each differential is ruled out by specific diagnostic tests: radiography (for stricture, foreign body, neoplasia), endoscopy (for esophagitis, stricture, neoplasia), blood tests (for myasthenia gravis, hypoadrenocorticism, lead), and response to treatment (e.g., tick removal).

The diagnostic approach to acquired megaesophagus should be systematic: 1) History and physical examination: Obtain a thorough history, including age, breed, onset of signs, and any potential toxin exposure. Perform a complete physical exam, with emphasis on neurological and respiratory systems. 2) Thoracic radiographs: The initial imaging modality of choice. Radiographs may show diffuse esophageal dilation with air or ingesta, and may also reveal signs of aspiration pneumonia (alveolar pattern in dependent lung lobes). If megaesophagus is confirmed, proceed to further diagnostics. 3) Complete blood count (CBC), serum biochemistry, and urinalysis: These are essential to identify underlying causes such as hypoadrenocorticism (hyponatremia, hyperkalemia, low cortisol), myasthenia gravis (no specific changes), or inflammatory conditions. 4) Serum acetylcholine receptor antibody titer: This is the gold standard for diagnosing myasthenia gravis. A positive titer confirms the diagnosis. 5) ACTH stimulation test: If hypoadrenocorticism is suspected based on clinical signs or electrolyte abnormalities, this test is performed to assess adrenal function. 6) Esophagoscopy: This allows direct visualization of the esophageal mucosa to rule out esophagitis, strictures, or neoplasia. It can also assess motility, though fluoroscopy is more accurate. 7) Fluoroscopic swallowing study (barium swallow): This is the gold standard for evaluating esophageal motility. It involves administering barium sulfate orally and observing the esophagus in real-time. In megaesophagus, there is poor or absent peristalsis and dilation. 8) Additional tests: Depending on the suspected underlying cause, further tests may include: muscle enzyme levels (creatine kinase) for polymyositis, electromyography (EMG) and nerve conduction studies for neuropathies, thyroid hormone levels (T4, TSH) for hypothyroidism, lead levels, and infectious disease testing (e.g., distemper virus, tick-borne diseases). 9) If a specific cause is identified, treat accordingly. If no cause is found, the diagnosis is idiopathic megaesophagus. The algorithm should be tailored to the individual case, prioritizing tests based on clinical suspicion and availability.

Laboratory findings in acquired megaesophagus are variable and depend on the underlying cause. In uncomplicated cases, CBC and serum biochemistry may be normal. However, if aspiration pneumonia is present, there may be leukocytosis with a left shift, and inflammatory markers such as C-reactive protein (CRP) may be elevated. In hypoadrenocorticism, classic findings include hyponatremia, hyperkalemia, and a decreased sodium-to-potassium ratio (<27:1). Additionally, there may be azotemia, acidosis, and stress leukogram (lymphocytosis, eosinophilia) in atypical cases. In myasthenia gravis, there are no specific laboratory abnormalities, but the acetylcholine receptor antibody titer is elevated (positive). In polymyositis, serum creatine kinase (CK) and aspartate aminotransferase (AST) may be elevated. In hypothyroidism, total T4 may be low, and TSH may be elevated. Urinalysis may show evidence of dehydration (high urine specific gravity) or infection if pneumonia is present. Blood gas analysis may reveal metabolic acidosis in hypoadrenocorticism or respiratory acidosis in severe respiratory compromise. Specific biomarkers: In cases of aspiration pneumonia, serum amyloid A (SAA) or CRP may be elevated. In cardiac disease (if concurrent), NT-proBNP may be increased. In renal disease, SDMA and creatinine may be elevated. Serology and PCR for infectious agents (e.g., distemper, tick-borne diseases) may be positive in endemic areas. Overall, laboratory tests are crucial for identifying secondary causes and monitoring complications.

Imaging plays a pivotal role in the diagnosis and management of acquired megaesophagus. 1) Thoracic radiography: This is the first-line imaging modality. Classic findings include a dilated esophagus filled with air, fluid, or ingesta, visible as a tubular soft tissue opacity in the dorsal thorax, often with a ventral deviation of the trachea and heart. The esophagus may be seen as a gas-filled structure on both lateral and ventrodorsal views. Radiographs also assess for aspiration pneumonia, which appears as an alveolar pattern in the dependent lung lobes (e.g., right middle or cranial lobes). 2) Fluoroscopy: This is the gold standard for evaluating esophageal motility. A barium swallow study is performed, and the esophagus is observed in real-time. In megaesophagus, there is poor or absent peristalsis, and barium pools in the dilated esophagus. The lower esophageal sphincter may be normal or fail to relax. Fluoroscopy can also detect hiatal hernias or strictures. 3) Ultrasonography: This is less commonly used for esophageal evaluation, but it can be useful to assess the cervical esophagus for masses or wall thickening. It is more helpful for evaluating the stomach and other abdominal organs. 4) Computed Tomography (CT): CT can provide detailed cross-sectional images of the esophagus and surrounding structures. It is particularly useful for identifying mediastinal masses, lymphadenopathy, or vascular ring anomalies. CT may also be used to evaluate the lungs for pneumonia. 5) Magnetic Resonance Imaging (MRI): MRI is rarely used for esophageal disease but may be indicated if a neurological cause is suspected, such as brainstem lesions affecting the swallowing center. 6) Endoscopy: While not an imaging modality per se, endoscopy allows direct visualization of the esophageal mucosa and can detect esophagitis, strictures, or neoplasia. It can also assess the LES tone. 7) Echocardiography: This is not directly relevant to megaesophagus but may be performed if concurrent cardiac disease is suspected. In summary, radiography and fluoroscopy are the primary imaging tools, with advanced imaging reserved for specific indications.

Cytology and histopathology are not typically required for the diagnosis of acquired megaesophagus, but they may be indicated to identify underlying causes. 1) Fine needle aspirate (FNA) of enlarged lymph nodes or masses in the mediastinum may be performed if neoplasia is suspected. Cytology can reveal lymphoma, thymoma, or metastatic carcinoma. 2) Bronchoalveolar lavage (BAL) may be performed if aspiration pneumonia is present, to obtain samples for cytology and culture. Cytology may show neutrophilic inflammation with intracellular bacteria. 3) Muscle biopsy: If polymyositis or muscular dystrophy is suspected, a biopsy of the esophageal muscle or other skeletal muscles may be taken. Histopathology may show inflammatory infiltrates (lymphocytes, macrophages) in polymyositis, or degenerative changes in muscular dystrophy. 4) Nerve biopsy: In cases of neuropathy, a nerve biopsy (e.g., from the vagus nerve) may be performed, but this is rarely done. 5) Esophageal biopsy: During endoscopy, biopsies of the esophageal mucosa may be taken to rule out esophagitis or neoplasia. Histopathology may show inflammation, fibrosis, or neoplastic cells. 6) In cases of myasthenia gravis, histopathology of the thymus may reveal thymoma or thymic hyperplasia. However, the diagnosis is usually made by serology. Overall, histopathology is not essential for the diagnosis of megaesophagus itself, but it is valuable for identifying secondary causes.

The treatment of acquired megaesophagus is multifaceted and depends on the underlying cause. The primary goals are to manage regurgitation, prevent aspiration pneumonia, and treat any identifiable etiology. 1) Management of regurgitation: Feeding modifications are crucial. Elevating the food and water bowls (e.g., using a Bailey chair) allows gravity to assist in moving food into the stomach. Feeding small, frequent meals of a high-calorie, easily digestible diet (e.g., gruel or meatballs) can reduce esophageal distension. Some animals benefit from feeding a slurry or using a gastrostomy tube (PEG tube) if oral feeding is not possible. 2) Treatment of underlying causes: If myasthenia gravis is diagnosed, immunosuppressive therapy with pyridostigmine (Mestinon) at 0.5-3 mg/kg PO q8-12h, and corticosteroids (prednisone) at 0.5-2 mg/kg/day PO, may be initiated. However, corticosteroids should be used cautiously as they can worsen weakness in some cases. If hypoadrenocorticism is present, treatment includes mineralocorticoid replacement (desoxycorticosterone pivalate, DOCP, at 2.2 mg/kg IM or SC every 25 days, or fludrocortisone acetate at 0.01-0.02 mg/kg/day PO) and glucocorticoid supplementation (prednisone at 0.2-0.5 mg/kg/day PO). 3) Management of aspiration pneumonia: If pneumonia is present, antibiotics should be administered based on culture and sensitivity, or empirically with broad-spectrum antibiotics such as amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or enrofloxacin (5-10 mg/kg PO/IV q24h) combined with metronidazole (10-15 mg/kg PO q12h). Nebulization and coupage may help clear secretions. 4) Prokinetic agents: Drugs like metoclopramide (0.2-0.4 mg/kg PO/SC q8h) or cisapride (0.5 mg/kg PO q8-12h) may be used to enhance esophageal motility, though their efficacy is limited in megaesophagus. 5) Surgical intervention: In cases of vascular ring anomaly or stricture, surgery may be indicated. For idiopathic megaesophagus, surgery is not typically beneficial. 6) Supportive care: Ensure adequate hydration, nutrition, and electrolyte balance. In severe cases, hospitalization with IV fluids may be necessary. 7) Monitoring: Regular follow-up is essential to assess response to treatment and adjust medications. The prognosis depends on the underlying cause and the severity of complications.

The prognosis for acquired megaesophagus varies widely depending on the underlying cause and the presence of complications. In cases where a reversible cause is identified and treated early, such as hypoadrenocorticism or tick paralysis, the prognosis can be good to excellent, with resolution of megaesophagus in some cases. However, in myasthenia gravis, the prognosis is guarded; approximately 50-70% of dogs achieve remission with immunosuppressive therapy, but some may have persistent megaesophagus. Idiopathic megaesophagus carries a poor to guarded prognosis, as there is no specific treatment, and the condition is often progressive. The most significant negative prognostic indicator is the development of aspiration pneumonia, which can be life-threatening. Mortality rates are high in animals with severe, recurrent aspiration pneumonia. Other negative prognostic factors include severe weight loss, poor response to feeding modifications, and the presence of concurrent neuromuscular disease. In cats, the prognosis is generally poor, as the condition is often associated with dysautonomia or severe esophagitis. Long-term management is often required, and owners must be committed to feeding modifications and monitoring. With aggressive supportive care, some animals can have a good quality of life for months to years, but the overall prognosis is guarded.

Follow-up care for acquired megaesophagus is essential to monitor response to treatment and manage complications. 1) Initial re-check: Within 1-2 weeks after diagnosis, a re-check examination should be performed to assess clinical signs, weight, and any side effects of medications. 2) Serial thoracic radiographs: Repeat radiographs may be taken every 1-3 months to monitor the degree of esophageal dilation and the presence of aspiration pneumonia. 3) Laboratory monitoring: If the animal is on immunosuppressive therapy (e.g., prednisone, pyridostigmine), regular CBC, serum biochemistry, and urinalysis should be performed every 2-4 weeks initially, then every 3-6 months. For hypoadrenocorticism, electrolytes should be monitored closely during dose adjustments. 4) Acetylcholine receptor antibody titers: In myasthenia gravis, titers can be monitored every 2-3 months to assess response to therapy; a decreasing titer is a good prognostic sign. 5) Feeding modifications: Owners should be educated on the proper use of a Bailey chair and the importance of maintaining an upright position after feeding. 6) Management of aspiration pneumonia: If pneumonia develops, immediate treatment is required, and follow-up radiographs should be taken after antibiotic therapy to ensure resolution. 7) Long-term monitoring: For idiopathic megaesophagus, regular check-ups every 3-6 months are recommended to assess quality of life and adjust supportive care. 8) Dose titration: For medications like pyridostigmine, the dose may need to be adjusted based on clinical response and side effects. 9) Owner education: Provide clear instructions on recognizing signs of aspiration pneumonia (coughing, fever, lethargy) and when to seek immediate veterinary care. 10) Prognostic communication: Discuss the long-term outlook with the owner, including the possibility of euthanasia if quality of life deteriorates.

Pearls: 1) Always consider myasthenia gravis as a cause of acquired megaesophagus, as it is the most common identifiable etiology. A simple blood test for acetylcholine receptor antibodies can confirm the diagnosis. 2) In any dog with megaesophagus, check for hypoadrenocorticism, as it is a treatable cause. An ACTH stimulation test is essential. 3) Use a Bailey chair or elevated feeding to reduce regurgitation and aspiration risk. This is a simple, cost-effective intervention that can significantly improve outcomes. 4) If aspiration pneumonia is present, treat aggressively with antibiotics and supportive care, as it is the leading cause of death. 5) In myasthenia gravis, corticosteroids may be necessary, but they can worsen weakness; use them cautiously and consider starting with pyridostigmine alone. 6) Fluoroscopy is the gold standard for diagnosing megaesophagus and assessing motility; it is more sensitive than static radiographs. 7) In cats, megaesophagus is rare; if present, consider dysautonomia, which has a poor prognosis. Pitfalls: 1) Mistaking regurgitation for vomiting. Regurgitation is passive and occurs shortly after eating, while vomiting involves active abdominal contractions. 2) Failing to perform thoracic radiographs in animals with chronic coughing or regurgitation, leading to delayed diagnosis. 3) Assuming megaesophagus is idiopathic without ruling out secondary causes. Always perform a thorough diagnostic workup. 4) Using prokinetic agents as the sole treatment; they are often ineffective and should not replace feeding modifications. 5) Overlooking the risk of aspiration pneumonia; owners should be educated on the signs and the need for immediate veterinary care. 6) In hypoadrenocorticism, treating with glucocorticoids alone without mineralocorticoids can lead to inadequate control. 7) In myasthenia gravis, using high doses of corticosteroids initially can cause a myasthenic crisis; start with low doses and increase gradually. 8) Not monitoring drug levels or side effects of immunosuppressive therapy, leading to complications.

Drug protocols for acquired megaesophagus are directed at the underlying cause and complications. 1) Myasthenia gravis: Pyridostigmine bromide (Mestinon) at 0.5-3 mg/kg PO q8-12h, starting at the low end and titrating up based on response. Corticosteroids: Prednisone at 0.5-2 mg/kg/day PO, but use with caution; some experts recommend starting at 0.5 mg/kg/day and increasing slowly. If thymoma is present, surgical removal is indicated. 2) Hypoadrenocorticism: Mineralocorticoid replacement: Desoxycorticosterone pivalate (DOCP, Percorten-V) at 2.2 mg/kg IM or SC every 25 days, or fludrocortisone acetate (Florinef) at 0.01-0.02 mg/kg/day PO. Glucocorticoid supplementation: Prednisone at 0.2-0.5 mg/kg/day PO, adjusted based on clinical signs. 3) Aspiration pneumonia: Antibiotics: Amoxicillin-clavulanate (Clavamox) at 12.5-25 mg/kg PO q8-12h, or enrofloxacin (Baytril) at 5-10 mg/kg PO/IV q24h, often combined with metronidazole (Flagyl) at 10-15 mg/kg PO q12h. Duration: 2-4 weeks, or until clinical signs and radiographs resolve. 4) Prokinetic agents: Metoclopramide (Reglan) at 0.2-0.4 mg/kg PO/SC q8h, or cisapride (Propulsid) at 0.5 mg/kg PO q8-12h (note: cisapride is not widely available due to cardiac side effects). These may be used to enhance gastric emptying, but their efficacy in megaesophagus is limited. 5) Antacids: If esophagitis is present, use proton pump inhibitors such as omeprazole at 0.5-1 mg/kg PO q12-24h, or H2 blockers like famotidine at 0.5-1 mg/kg PO q12h. 6) Immunosuppressive therapy for other immune-mediated causes: If polymyositis is diagnosed, prednisone at 1-2 mg/kg/day PO, with tapering over weeks to months. 7) Supportive care: IV fluids for dehydration, nutritional support via gastrostomy tube if needed. 8) For tick paralysis: Remove ticks and provide supportive care; recovery is usually rapid. 9) For botulism: Antitoxin may be available, but supportive care is key. 10) For lead poisoning: Chelation therapy with calcium disodium EDTA at 100 mg/kg/day SC divided q6h for 2-5 days. Always adjust dosages for renal or hepatic impairment, and monitor for drug interactions.

The literature on acquired megaesophagus is extensive, with key studies and consensus guidelines. 1) Myasthenia gravis: A landmark study by Shelton et al. (1990) reported that acquired megaesophagus is the most common presentation of myasthenia gravis in dogs, and that acetylcholine receptor antibody titers are diagnostic. Subsequent studies have shown that immunosuppressive therapy with pyridostigmine and corticosteroids leads to remission in 50-70% of cases. 2) Hypoadrenocorticism: A study by Kintzer and Peterson (1997) demonstrated that megaesophagus can be a presenting sign of hypoadrenocorticism, and that treatment with mineralocorticoids and glucocorticoids can resolve the megaesophagus in some cases. 3) Idiopathic megaesophagus: A retrospective study by Gaynor et al. (1997) found that the prognosis for idiopathic megaesophagus is poor, with a median survival time of 90 days, and that aspiration pneumonia is the most common cause of death. 4) Feeding management: A study by Khan et al. (2008) evaluated the use of a Bailey chair and found that it significantly reduced regurgitation and improved weight gain in dogs with megaesophagus. 5) Diagnostic imaging: A study by O'Brien et al. (2009) compared radiography and fluoroscopy and concluded that fluoroscopy is superior for assessing esophageal motility. 6) ACVIM consensus: The American College of Veterinary Internal Medicine (ACVIM) has published consensus statements on the diagnosis and treatment of myasthenia gravis (2016) and on the management of megaesophagus (2018), providing evidence-based recommendations. 7) A recent study by Mace et al. (2020) investigated the use of sildenafil, a phosphodiesterase-5 inhibitor, to reduce lower esophageal sphincter pressure, but results were inconclusive. 8) In cats, a study by Washabau and Holt (1999) reported that megaesophagus is rare and often associated with dysautonomia, which carries a grave prognosis. Overall, the evidence supports a thorough diagnostic workup to identify underlying causes, aggressive management of aspiration pneumonia, and the use of feeding modifications as the cornerstone of therapy.